2023 was a tricky yr for your biopharma sector, with numerous companies downsizing and restructuring their workforces to remain afloat. You can find signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and lifestyle sciences industry in the latter Element of 2023 and have continued their upswing https://sites.google.com/view/bio-sites/blog